van den Ende, Roy P. J. http://orcid.org/0000-0002-0233-4229
Peters, Femke P.
Harderwijk, Ernst
Rütten, Heidi
Bouwmans, Liza
Berbee, Maaike
Canters, Richard A. M.
Stoian, Georgiana
Compagner, Kim
Rozema, Tom
de Smet, Mariska
Intven, Martijn P. W.
Tijssen, Rob H. N.
Theuws, Jacqueline
van Haaren, Paul
van Triest, Baukelien
Eekhout, Dave
Marijnen, Corrie A. M.
van der Heide, Uulke A.
Kerkhof, Ellen M.
Funding for this research was provided by:
KWF Kankerbestrijding (UL2013-6311)
Article History
Received: 9 October 2019
Accepted: 10 February 2020
First Online: 18 February 2020
Ethics approval and consent to participate
: The STAR-TReC trial complies with the standards of the Declaration of Helsinki and current ethical guidelines and was reviewed and approved by an ethical committee (CMO region Arnhem-Nijmegen (Nijmegen), approval number NL53181.091.16). This treatment planning study is a substudy of the STAR-TReC trial (ExternalRef removed Identifier: ExternalRef removed). All patients signed written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.